Plasma and Urine Dimercaptopropanesulfonate Concentrations after Dermal Application of Transdermal DMPS (TD-DMPS)

详细信息    查看全文

• 作者：Jennifer P. Cohen (1)
  Anne-Michelle Ruha (1)
  Steven C. Curry (1)
  Kallol Biswas (2)
  Benjamin Westenberger (2)
  Wei Ye (2)
  Kathleen L. Caldwell (3)
  Frank LoVecchio (1) (4)
  Keith Burkhart (2)
  Nasr Samia (2)
  
• 关键词：DMPS ; Chelation ; Mercury ; Autism
• 刊名：Journal of Medical Toxicology
• 出版年：2013
• 出版时间：March 2013
• 年：2013
• 卷：9
• 期：1
• 页码：9-15
• 全文大小：140KB
• 参考文献：1. Wax PM, Thornton CA (2000) Recovery from severe arsenic-induced peripheral neuropathy with 2,3-dimercapto-1-propanesulphonic acid. J Tox Clin Tox 38(7):777-0 CrossRef
  2. Buttar RA. Buttar Autism Treatment Protocol. http://www.defeatautismyesterday.com/tddmpspro.pdf. Accessed September 10, 2012
  3. Gonzalez MA (2012) http://www.testmyhormones.com/topical_transdermal_dmps_for_autism.htm. Accessed September 10, 2012
  4. Layton R (2012) http://www.allergyconnection.com/autism_dmpsprotocol.html. Accessed September 10, 2012
  5. Alibhai T (2012) http://www.vitaliahealthcare.ca/chelation.html. Accessed September 10, 2012
  6. Koles E (2012) http://www.u-ok.net/chelation_chicago.html. Accessed September 10, 2012
  7. Mitka M (2008) Chelation therapy trials halted. JAMA 300(19):2236
  8. Ruha AM, Curry SC, Gerkin RD, Caldwell KL, Osterlok JD, Wax PM (2009) Urine mercury excretion following meso-dimercaptosuccinic acid challenge in fish eaters. Arch Pathol Lab Med 133(1):87-2
  9. Aposhian HV, Maiorino RM, Gonzalez-Ramirez D et al (1995) Mobilization of heavy metals by newer, therapeutically useful chelating agents. Toxicology 97:23-8
  10. Maiorino RM, Weber GL, Aposhian HV (1986) Fluorometric determination of 2,3-dimercaptopropne-1-sulfonic acid and other dithiols by precolumn derivatization with bromobimane and column liquid chromatography. J Chromatog 374(2):297-10
  11. Maiorino RM, Barry TJ, Aposhian HV (1987) Determination and metabolism of dithiol chelating agents: electrolytic and chemical reduction of oxidized dithiols in urine. Anal Biochem 160(1):217-26
  12. Caldwell KL, Mortensen ME, Jones RL, Caudill S, Osterloh JD (2009) Total blood mercury concentrations in the U.S. population: 1999-2006. Int J Hyg Environ Health 212:588-98
  13. National Center for Environmental Health (2012) The fourth national report on human exposure to environmental chemicals, Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, updated February 2012, p 144
  14. Aposhian HV (1998) Mobilization of mercury and arsenic in humans by sodium 2,3-dimercapto-1-propane sulfonate (DMPS). Environ Health Perspect 106(suppl 4):S1017–S1025
  15. Baker JP (2008) Mercury, vaccines, and autism. Am J Public Health 98(2):244-53
  16. Meadows M (2004) IOM report: no link between vaccines and autism. FDA Consum 38(5):18-
  17. Institute of Medicine (2012) Immunization safety review: vaccine and autism. Institute of Medicine. http://www.iom.edu/Reports/2004/Immunization-Safety-Review-Vaccines-and-Autism.aspx. Accessed on September 10, 2012
  18. Maiorino RM, Dart RC, Carter DE, Aposhian HV (1991) Determination and metabolism of dithiol chelating agents. XII. Metabolism and pharmacokinetics of Sodium 2,3-dimercaptopropane-1-sulfonate in humans. J Pharmacol Exp Ther 259(2):808-14
  19. Hurlbut KM, Maiorino RM, Mayersohm M, Dart RC, Bruce DC, Aposhian HV (1994) Determination and metabolism of dithiol chelating agents XVI: pharmacokinetics of 2,3-dimercapto-1-propanesulfonate after intravenous administration in human volunteers. J Pharmacol Exp Ther 268(2):662-
  20. Hruby K, Donner A (1987) 2,3-Dimercapto-1-propanesulphonate in heavy metal poisoning. Med Toxicol 2:317-23
  21. Sullivan JB, Krieger GR (2001) Clinical environmental health and toxic exposures, 2nd edn. Lippincott Williams and Wilkins, Philadelphia, p 53
  22. Aposhian HV, Bruce DC, Alter W, Dart RC, Hurlbut KM, Aposhian M (1992) Urinary mercury after administration of 2,3-dimercaptopropoane-1-sulfonic acid: correlation with dental amalgam score. FASEB J 6:2472-476
  
• 作者单位：Jennifer P. Cohen (1)
  Anne-Michelle Ruha (1)
  Steven C. Curry (1)
  Kallol Biswas (2)
  Benjamin Westenberger (2)
  Wei Ye (2)
  Kathleen L. Caldwell (3)
  Frank LoVecchio (1) (4)
  Keith Burkhart (2)
  Nasr Samia (2)
  
  1. Department of Medical Toxicology, Banner Good Samaritan Medical Center, 925 E. McDowell Rd., 2nd Floor, Medical Toxicology, Phoenix, AZ, 85006, USA
  2. Division of Pharmaceutical Analysis, U.S. FDA, 10903 New Hampshire Avenue, Silver Spring, MD, USA
  3. Division of Laboratory Sciences, National Center for Environmental Health, CDC, 1600 Clifton Rd., Atlanta, GA, 30333, USA
  4. Department of Emergency Medicine, Maricopa Medical Center, Phoenix, AZ, USA
  
• ISSN：1937-6995

文摘

2,3-Dimercaptopropane-1-sulfonate (DMPS) is a metal chelator approved in Europe for oral or intravenous use for heavy metal poisoning. Transdermally applied DMPS (TD-DMPS) is used by some alternative practitioners to treat autism, despite the absence of evidence for its efficacy. We found no literature evaluating the pharmacokinetics of the transdermal route of delivery or the ability of TD-DMPS to enhance urinary mercury elimination. We hypothesized that TD-DMPS is not absorbed. Eight adult volunteers underwent application of 1.5- drops/kg of TD-DMPS. Subjects provided 12-h urine collections the day before and day of application. Subjects underwent blood draws at 0, 30, 60,90, 120, and 240?min after TD-DMPS application. Plasma and urine were assayed for the presence of DMPS. Urine was assayed for any change in urinary mercury excretion after DMPS. One control subject ingested 250?mg of oral DMPS and underwent the same urine and blood collections and analyses. No subject had detectable urine DMPS or increased urine mercury excretion after TD-DMPS. One subject had detectable levels of DMPS in the 30-min plasma sample, suspected to be contamination. All other samples for that subject and the other seven subjects showed no detectable plasma DMPS. The control subject had detectable urine and plasma DMPS levels and increased urine mercury excretion. These results indicate that TD-DMPS is not absorbed. There was no increase in urine mercury excretion after TD-DMPS. Our results argue that TD-DMPS is an ineffective metal chelator.